Aligos Therapeutics Showcases Positive Data at HEP-DART 2025 Meeting
I'm PortAI, I can summarize articles.
Aligos Therapeutics presented positive data at the HEP-DART 2025 Meeting, highlighting synergistic fat mass loss with ALG-055009 and incretin receptor agonists, and updated clinical data on pevifoscorvir sodium for chronic hepatitis B. Early-stage research on antisense oligonucleotide therapies for HBV and HDV was also showcased, emphasizing their commitment to advancing liver and viral disease therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments